Naheed Rahman, business lead consultant at Envigo, assesses the ongoing Brexit chal
Lonza Pharma & Biotech has concluded an agreement, under which GE Hea
Genoa-based Italmatch Ch
DSM Sinochem Pharmaceuticals has new identity under private eq
Do you aspire to develop products that address the world’s biggest issues or unlock the most exciti
Biobased solvents, such as those derived from lactate esters, are a solution for safer, more sustainable agrichemicals.
MilliporeSigma (MS) known in Europe as Merck, is opening a US$20 million, 3,800m2 biologics testing laboratory in Singapore – the first of its kind outside the US and UK and the first in Singapore.
Sustainable technology company Anellotech has confirmed significant progress in its Bio-TCat technology development programme and has begun planning for scale- up design and engineering of a commercial plant with its process development and design partner IFPEN and commercialisation, engineering
Bayer spin-off and polymer materials company, Covestro, is investing €1.5 billion (US$1.7 billion) in the construction of a world-scale methylene diphenyl diisocyanate (MDI) plant in Baytown, US. The investment at the existing site is the largest single investment in the history of the company.
Most Popular
Building work on Fera Science Limited’s new mesocosm testing facility is nearing completion in Sand Hutton, near York, UK. The E-Flows mesocosm is a groundbreaking project developed in partnership by Fera (formerly the Food and Environment Research Agency), the Centre for Crop Health and Protection (CHAP) and supported by Innovative UK. It has been designed, developed and will be managed and operated by Fera for use by the agri-tech industry and researchers.
MilliporeSigma (MS) known in Europe as Merck, is opening a US$20 million, 3,800m2 biologics testing laboratory in Singapore – the first of its kind outside the US and UK and the first in Singapore. Biologics testing is a major step in the drug development process to ensure sterility, safety and overall quality of customers’ biological drug products.
Boehringer Ingelheim (BI) has started the construction of a new production facility for innovative drugs. The new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches.
The research-driven pharmaceutical company is investing €85 million (US$99.3 million) in Ingelheim, focusing on modern and flexible production.
